J&J Acquires Atraverse Medical: Cardiac Ablation Access Technology and the Electrophysiology M&A Wave

The Deal at a Glance

On April 24, 2026, Johnson & Johnson (NYSE: JNJ) entered into a definitive agreement to acquire Atraverse Medical, Inc., a privately held medical device company based in San Diego, California, that specializes in next-generation left-heart access and radiofrequency (RF) technology for cardiac electrophysiology procedures.

Financial terms were not disclosed. The transaction is expected to close in Q2 2026, subject to customary closing conditions. Once completed, the acquisition will place Atraverse's technology within J&J's Biosense Webster division, which is the company's electrophysiology-focused subsidiary and a global leader in cardiac mapping and ablation systems.

The Technology: Why Left-Heart Access Matters

To understand this acquisition, it helps to understand a specific technical challenge in cardiac electrophysiology. Atrial fibrillation (AF) — the most common cardiac arrhythmia, affecting over 40 million people worldwide — is frequently treated with catheter ablation. During this procedure, an electrophysiologist threads a catheter through blood vessels into the heart to create lesions (scar tissue) that block abnormal electrical signals.

The problem: the left atrium, where most AF ablation is performed, has no direct venous pathway. The only way to reach it from the right side of the heart is to puncture through the interatrial septum — the wall between the left and right atria. This transseptal puncture is one of the most technically demanding and potentially dangerous steps in the entire procedure.

Current approaches rely on transseptal needles and steerable sheaths — mechanical tools that require significant skill to use safely. Complications from transseptal puncture can include cardiac tamponade, aortic root puncture, and other serious adverse events.

The HOTWIRE Solution

Atraverse's HOTWIRE Transseptal Access System addresses this challenge with a fundamentally different approach:

1. Radiofrequency (RF) guidewire — Instead of a mechanical needle, HOTWIRE uses an RF guidewire that generates controlled thermal energy to create a precise opening in the interatrial septum.
2. Impedance-guided technology — The system monitors tissue impedance in real time. When the guidewire crosses the septum, the impedance change triggers an automatic shutoff of RF energy, preventing unnecessary energy delivery to the left atrium.
3. Zero-exchange workflow — The guidewire acts as both the access tool and a rail for catheter-based therapy systems, eliminating the need to exchange devices during the procedure.
4. Clear tip visibility under intracardiac echocardiography (ICE) — Physicians can visualize the guidewire tip throughout the procedure, enhancing safety.

The RF guidewire received FDA clearance in May 2024, with a limited US market release initiated thereafter. The fully integrated system (guidewire plus RF generator) received FDA clearance in December 2025.

Clinical Evidence

At the AF Symposium 2026 in Boston (February 2026), Atraverse presented data from a first-in-human observational study of approximately 500 patients, showing:

• 100% procedural success rate
• Strong safety profile with impedance-guided automatic energy shutoff
• Consistency of results across preclinical and first-in-human studies

Dr. Steven Mickelsen, Atraverse co-founder and Chief Translational Science Officer, stated: "These data reinforce the clinical importance of controlled RF delivery and impedance-guided shutoff during transseptal access. The consistency of results highlights the strength of the Hotwire platform and its potential to set a new standard for left-heart access."

The Founders: A Track Record of MedTech Success

The Atraverse founding team has a notable track record that adds strategic context to this acquisition:

• Steven Mickelsen, MD — A pioneer in the pulsed field ablation (PFA) space. He founded Farapulse in 2012, which Boston Scientific acquired in 2021 for $295 million upfront (with additional milestone payments). The Farapulse technology is now one of Boston Scientific's trademark electrophysiology offerings. Mickelsen also founded Field Medical in 2022.
• John Slump — Co-founded Farapulse alongside Mickelsen and serves as Atraverse's CEO.
• Eric Sauter — Co-founded Atraverse and serves in a leadership role.

This is essentially the same team that created Farapulse, which became a cornerstone of Boston Scientific's electrophysiology strategy. J&J's acquisition of their next venture signals strong conviction in both the technology and the team's ability to execute.

J&J's Electrophysiology Strategy: Building the Full Stack

The Atraverse acquisition is the latest move in J&J's multi-year campaign to build a comprehensive electrophysiology platform. The company has been investing aggressively in this space, both organically and through acquisitions:

Recent J&J Electrophysiology Moves

The Atraverse technology complements J&J's existing electrophysiology portfolio — including the Varipulse PFA platform and the Carto 3 mapping system (both under Biosense Webster) — by improving the access step that precedes ablation. As one industry analyst noted, this acquisition "joins and complements the Shockwave and Abiomed technologies."

The Varipulse Challenge

J&J's Varipulse PFA system, which uses pulsed electric fields to create cardiac lesions without thermal damage, has been a key competitive initiative. However, the company temporarily halted US sales in 2025 after reports of neurovascular events in patients. While sales have since resumed with enhanced safety protocols, the episode highlighted the technical complexity and regulatory risk inherent in cardiac ablation technology.

Adding Atraverse's access technology may help de-risk future procedures by making the transseptal puncture step more controlled and consistent — potentially reducing the procedural variability that can contribute to adverse events.

The Competitive Landscape: Electrophysiology's M&A Wave

The electrophysiology market — estimated at over $10 billion globally and growing at double-digit rates — has been one of the most active areas for medtech M&A. According to GlobalData analysis, the global electrophysiology ablation catheter market alone is projected to grow from $6.1 billion in 2025 to approximately $17.6 billion by 2035, at a CAGR of 11.1%. J&J's Biosense Webster division held a dominant 43.1% share of the US electrophysiology ablation catheter market in 2025, well ahead of Boston Scientific (25.6%) and Medtronic (24.6%).

Key Players and Their Strategies

Boston Scientific has been the early leader in pulsed field ablation with Farapulse (now FDA-approved since January 2024). J&J is racing to close the gap. The Atraverse acquisition gives J&J another differentiating technology — improved access — that could make its ablation platform more attractive to electrophysiologists.

PFA: The Defining Technology Shift

Pulsed field ablation (PFA) is rapidly replacing traditional thermal ablation (radiofrequency and cryo) as the preferred approach for atrial fibrillation ablation. PFA uses ultra-short electrical pulses to create irreversible electroporation in cardiac tissue — effectively killing cells through electrical disruption rather than thermal injury. Key advantages:

• Tissue selectivity (less collateral damage)
• Faster procedures
• Reduced risk of pulmonary vein stenosis and esophageal injury

The global PFA market is projected to grow rapidly, creating a winner-take-most dynamic among the major electrophysiology companies. Access technology like Atraverse's HOTWIRE becomes a complement to PFA — making the overall procedure safer and more efficient.

Implications for the MedTech Industry

What This Means for Device Manufacturers

1. Procedure-enabling technologies are undervalued. While most attention in electrophysiology focuses on ablation technology (PFA, RF, cryo), the access step is equally critical. Atraverse's acquisition shows that improving procedural steps — not just the headline therapy — creates significant value. Companies developing workflow-improving technologies in other procedure areas should take note.

2. Repeat founders attract premium valuations. The Atraverse founding team's prior success with Farapulse (acquired by Boston Scientific for $295M) likely influenced J&J's willingness to acquire their next venture relatively early in its commercialization. For medtech entrepreneurs, building a track record of successful exits compounds value.

3. Tuck-in M&A remains the dominant pattern. J&J's acquisition of Atraverse is a classic tuck-in deal — a relatively small acquisition that adds a specific capability to an existing platform. This pattern is likely to continue as large-cap medtech companies build comprehensive procedural solutions.

What This Means for Hospitals and Electrophysiologists

1. Improved procedural safety. HOTWIRE's impedance-guided automatic shutoff mechanism could reduce complications from transseptal puncture, one of the highest-risk steps in AF ablation.

2. Workflow efficiency. The zero-exchange design eliminates device swaps during the procedure, potentially reducing procedure time and improving lab throughput.

3. Platform integration. Within J&J's Biosense Webster ecosystem, HOTWIRE could be integrated with Carto 3 mapping and Varipulse ablation into a streamlined procedural workflow.

Key Takeaways

• J&J agreed to acquire Atraverse Medical on April 24, 2026, adding the FDA-cleared HOTWIRE Transseptal Access System to its cardiac ablation portfolio
• HOTWIRE uses RF guidewire technology with impedance-guided automatic shutoff for safer left-heart access during AF ablation procedures
• The Atraverse founding team previously created Farapulse, which Boston Scientific acquired for $295M — giving J&J a team with a proven track record in EP innovation
• The acquisition is part of J&J's broader electrophysiology platform strategy, complementing Varipulse (PFA), Carto 3 (mapping), Shockwave (IVL), and Abiomed (circulatory support)
• The electrophysiology market (> $10B) is experiencing intense M&A activity driven by the shift from thermal ablation to PFA
• For the medtech industry, the deal highlights the growing value of procedure-enabling technologies and workflow-improving innovations in interventional medicine
• The transaction is expected to close in Q2 2026; financial terms were not disclosed